Vertex Pharmaceuticals Incorporated
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| VRTX.MX | 068270.KS | CSL.AX | KRYS | ROIV | BBIO | |
|---|---|---|---|---|---|---|
| Market cap | 2.41T | 45.19T | 93.12B | 9.45B | 24.86B | 13.23B |
| P/E (TTM) | 31.2 | — | — | 40.0 | — | — |
| Forward P/E | — | — | 20.4 | 35.3 | -20.0 | -265.0 |
| Price/book | 6.8 | — | 4.4 | 7.0 | 5.9 | -5.3 |
| Dividend yield | — | 0.37% | 2.11% | — | — | — |
| 1-year change | +23.38% | +15.02% | −11.70% | +61.55% | +89.01% | +18.02% |
| Today | 0.00% | +2.16% | +0.96% | +0.85% | +2.65% | +1.93% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All VRTX.MX news ›3,678 Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Banque Pictet & Cie SA
Posted by Defense World Staff on Oct 17th, 2026 NASDAQ:VRTX opened at $499.74 on Friday. The stock’s fifty day moving average is $523.54 and its 200 day moving average is $480.55. Vertex Pharmaceuticals Incorporated has a fifty-two week…
How Vertex Pharmaceuticals Incorporated (VRTX) Affects Rotational Strategy Timing
Stock Traders Daily Key findings for Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) - Weak Near and Mid-Term Sentiment Could Challenge Long-Term Positive Outlook - Exceptional 25.9:1 risk-reward short setup targets 7.5% downside vs…
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653
www.marketscreener.com Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653 Published on 10/15/2026 at 06:40 am EDT
Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children
Vertex Pharmaceuticals said Friday that new interim data from an open-label extension study evaluating Alyftrek in cystic fibrosis showed that some pediatric patients aged 2 to 5 years recovered... Vertex Pharmaceuticals Says Alyftrek…
Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference
Vertex Pharmaceuticals Incorporated announced new interim data from the ALYFTREK® 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children...
Citi Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
The Globe and Mail Citi analyst Geoff Meacham maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $585.00. Meacham covers the Healthcare sector, focusing on stocks such as Amgen, Regeneron, and Bristol-Myers…
DC Circuit Agrees Vertex Pharmaceuticals’ Fertility Support Program Would Violate Anti-Kickback Statute
On September 4, the US Court of Appeals for the DC Circuit ruled that the US Department of Health and Human Services Office of the Inspector General (HHS-OIG) properly found that Vertex Pharmaceuticals’ Fertility Support Program would…
Vertex Pharmaceuticals announces $10 billion acquisition: Can VRTX reverse weak momentum?
Traders Union
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Can the pioneer of mRNA vaccines outpace the king of cystic fibrosis treatments? Choosing between Moderna (MRNA -5.00%) and Vertex Pharmaceuticals (VRTX -0.60%) requires weighing high-growth potential against established, profitable market…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
marketscreener.com16
-
fool.com6
-
theglobeandmail.com4
-
defenseworld.net3
-
themarketsdaily.com3
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 57 articles, not a forecast.